The present disclosure provides compounds that are inhibitors of PIKfyve and/or PI3 kinases, and are therefore useful for the treatment of neurological diseases that are treatable by inhibition of PIKfyve. Also provided are pharmaceutical compositions containing such compounds, and methods of treatment using such compounds.

Disclosed are a compound preparation for neuranagenesis, and a preparation method therefor and the use thereof. The compound preparation for neuranagenesis comprises the raw medicinal materials in parts by weight: 10-20 parts of raw Astragali radix, 10-20 parts of Rehmaimiae Radix praeparata, 10-20 parts of Actyranthes bidentata, 6-15 parts of Jujubae fructus, 6-15 parts of Lycii fructus, 6-15 parts of parched Ziziphi spinosae semen, 6-12 parts of Angelicae smensis radix, 3-9 parts of Carthami flos, 6-15 parts of Poria, 6-15 parts of parched Atractylodis macrocephalae rhizoma and 10-20 parts of Zaocys. The compound preparation can be used for preparing drugs to treat nerve damage diseases, and can be prepared into oral liquids, granules, dissolved granules and tablets.

Compositions for CDKL5 gene therapy are provided, as well as recombinant CDKL5 proteins. Such CDKL5 gene therapy compositions and/or recombinant CDKL5 proteins may incorporate cell-penetrating polypeptides and/or leader signal polypeptides. Also provided are methods of producing such gene therapy compositions and recombinant CDKL5 proteins, as well as pharmaceutical compositions, methods of treatment, and uses of the gene therapy compositions and recombinant CDKL5 proteins.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.

A compound represented by the formula (I):

##STR00001##

wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.

A compound represented by the formula (I):

##STR00001##

wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Disclosed are novel hydroxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced synthetically or biosynthetically.

Disclosed are novel aldehyde and ketone psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with an aldehyde or ketone group containing compound.

Disclosed are novel nitrated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The nitrated psilocybin derivative compounds may be chemically synthesized or biochemically synthesized in host cells.

Disclosed are novel carboxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a carboxyl or Carboxylic acid derivative containing compound.

Provided herein are compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease